Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SCYNEXIS, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for difficult-to-treat infections, particularly in the area of antifungal treatments. Its lead product candidate, SCY-078, targets invasive fungal infections and has shown promising results in clinical trials, positioning the company to address significant unmet medical needs in the healthcare sector.
SCYNEXIS primarily focuses on developing antifungal therapies, with SCY-078 being its flagship product. The company aims to monetize its innovations through product sales post-approval, licensing agreements, and grants for research. Its competitive advantage lies in its proprietary technology and a strong pipeline addressing high unmet needs in antifungal treatments, which are often resistant to existing therapies.
Clinical trial results for SCY-078, particularly Phase 3 outcomes
Regulatory approvals from the FDA or EMA
Partnership announcements or licensing deals with larger pharmaceutical companies
Market adoption rates post-launch
Regulatory changes impacting drug approval processes
Technological disruption in antifungal treatment methodologies
Emergence of alternative therapies from larger pharmaceutical companies
Generic competition post-patent expiration
High cash burn rate leading to potential liquidity issues
Dependence on external funding for R&D
low - The demand for antifungal treatments is relatively inelastic, as these are essential medications regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for R&D funding, impacting the company's ability to finance its clinical trials.
minimal - The company's low debt levels (Debt/Equity of 0.05) reduce credit risk.
growth - Investors looking for high-risk, high-reward opportunities in biotech.
high - The stock is likely to exhibit high volatility due to binary outcomes from clinical trials.
